Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to participate, have signed a consent form, and are expected to follow the study requirements
• People who are 18 years of age or older, of any gender, with a good general health and activity level (ECOG score 0–1), and an expected survival of at least 3 months
• People diagnosed with stage IIA to IIIA non-small cell lung cancer (a specific type and stage of lung cancer), who previously received a combination of immune checkpoint therapy (PD-1/PD-L1 inhibitors) and chemotherapy before surgery, and who then had surgery where all visible cancer was successfully removed (called R0 resection), staged using the AJCC/UICC 8th edition lung cancer staging system
• People whose cancer did not fully disappear after the pre-surgery treatment (i.e., did not achieve a pathological complete response), and who are between 4 and 12 weeks past their surgery at the time of receiving the first study treatment
• People whose major organs (such as heart, liver, and kidneys) are functioning well enough to meet the study's health standards
• Women of childbearing age who agree to use effective contraception during the study and for 6 months afterward, and who have a negative pregnancy test within 7 days before joining; men who agree to use effective contraception during the study and for 6 months afterward

Who may not be able to join:

• People who have had, or currently have, another type of cancer within the past 5 years — with two exceptions: cancers that were fully treated with a single surgery and have been free of disease for 5 continuous years, or certain low-risk, cured cancers such as early-stage cervical cancer in situ, non-melanoma skin cancers, or certain superficial bladder cancers
• People whose cancer has a known genetic change (mutation) for which targeted drug treatments have already been approved — people with non-squamous cell lung cancer are required to have had EGFR or ALK gene testing done or to provide previous test results
• People with certain heart or blood vessel conditions, including: a history of heart failure or significant heart rhythm blockage (Grade II or higher); a past or current heart attack or unstable chest pain, or irregular heart rhythms requiring treatment; or a blood clot or stroke-related event (such as a mini-stroke, brain bleed, brain infarction, deep vein clot, arterial clot, or pulmonary embolism) within the past 6 months
• People who have participated in another clinical drug trial within the past 30 days
• People who have taken certain traditional Chinese medicines with anti-tumour indications (as listed in China's NMPA-approved drug instructions) within the 2 weeks before starting the study treatment
• People who have had a major surgical procedure (other than the lung cancer removal surgery) within the 4 weeks before starting the study treatment, or who the investigating doctor determines are not suitable for the study for other reasons

Important: Always verify eligibility with the trial site directly before applying.